Rani Therapeutics Holdings Business Summary

Rani Therapeutics Holdings, Inc. (RANI) is a clinical-stage biotherapeutics company that generates revenue through strategic licensing, milestone-based collaboration agreements, and technology transfer fees. Its operations are concentrated in a single business segment: Orally Administered Biologics, centered on the proprietary RaniPill platform—a "robotic" capsule designed to deliver large molecules like peptides and antibodies transenterically. The company’s current commercial roadmap is anchored by a $1.085 billion collaboration with Chugai Pharmaceutical and the January 2026 initiation of Phase 1 trials for RT-114, an oral obesity treatment. Direct competitors include Oramed Pharmaceuticals, Biora Therapeutics, and Entera Bio; Rani differentiates itself by using a mechanical delivery mechanism that achieves bioavailability levels comparable to subcutaneous injections, positioning it as a superior alternative to peers utilizing chemical permeation enhancers. The company was founded by Executive Chairman Mir Imran, a prolific medical inventor with over 400 patents who has founded more than 20 life science companies. The leadership team is headed by CEO Talat Imran, a former healthcare venture capitalist, and includes CFO Svai Sanford, who brings over 25 years of financial expertise from VIVUS and KPMG, and CSO Mir Hashim. In January 2026, Alireza Javadi was promoted to Chief Technical Officer to lead R&D and manufacturing automation, while Kate McKinley serves as Chief Business Officer. Rani’s high-pedigree investor base includes Samsara BioCapital, RA Capital Management, and Alphabet (Google), with a board of directors featuring strategic leaders like Abraham Bassan of Samsara and Vasudev Bailey of Anomaly Ventures.